Arvinas, Inc. (ARVN): Total Liabilities
$284.00M
As of 2025-12-31
$112.90M
As of 2026-06-30
-26.1%
3-year compound annual growth
+30.4%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $284.00M | -46.4% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $529.70M | -17.8% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $644.60M | -8.4% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $703.90M | -12.0% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $799.90M | +963.7% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $75.20M | +0.3% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $74.96M | +19.7% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $62.61M | -6.0% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $66.60M | n/a | 2019-03-26, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $284.00M | -46.4% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $543.42M | +388.1% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $34.89M | -21.3% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $343.95M | +27.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗